Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-09-09
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00091299
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00014352
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 397
- Registration Number
- NCT00004054
- Locations
- 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Registration Number
- NCT00024297
- Locations
- 🇬🇧
Birmingham Heartlands and Solihull NHS Trust -Teaching, Birmingham, England, United Kingdom
🇬🇧Essex County Hospital, Colchester, England, United Kingdom
🇬🇧Princess Royal Hospital, Hull, England, United Kingdom
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
- Conditions
- Interventions
- First Posted Date
- 2002-07-22
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 2305
- Registration Number
- NCT00041938
- Locations
- 🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Morehouse School of Medicine, Atlanta, Georgia, United States
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
- Conditions
Aspirin Or Warfarin To Prevent Stroke
- Conditions
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Treatment for Blood Clots in the Veins of the Legs
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 20
- Registration Number
- NCT00001713
- Locations
- 🇺🇸
National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States
Post Coronary Artery Bypass Graft (CABG) Study
- Conditions
Prevention of Recurrent Venous Thromboembolism (PREVENT)
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.